Population toxicokinetics of benzene

Environmental Health Perspectives

Volumn 104, Issue SUPPL. 6, 1996, Pages 1405-1411

  Bois, Frédéric Yves ^a,c   Jackson, Elise T ^a   Pekari, Kaija ^b   Smith, Martyn T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c INSERM   (France)

Author keywords

Benzene; Gibbs sampling; Human exposure; Metabolism; Toxicokinetics

Indexed keywords

BENZENE;

BAYES THEOREM; BIOLOGY; BONE MARROW; COMPUTER MODEL; CONFERENCE PAPER; MEASUREMENT; METABOLISM; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TOXICOKINETICS;

EID: 0030460451     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.961041405     Document Type: Conference Paper

References (36)

1. Snyder R, Kalf G. A perspective on benzene leukemogenesis. Grit Rev Toxicol 24:177-209 (1994).
2. Bois FY, Zeise L, Tozer TN. Precision and sensitivity analysis of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats and humans. Toxicol Appl Pharmacol 102:300-315 (1990).
3. Andersen ME, Krewski D, Withey JR. Physiological pharmacokinetics and cancer risk assessment. Cancer Lett 69:1-14 (1993).
4. Balant LP, Gex-Fabry M. Physiological pharmacokinetic modelling. Xenobiotica 20:1241-1257 (1990).
5. Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72:1103-1127 (1983).
6. Spear R, Bois F. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results. Environ Health Perspect 102 (Suppl 11):61-66 (1994).
7. Racine-Poon A, Smith AF. Population models. In: Statistical Methodology in the Pharmaceutical Sciences (Berry DA, ed). New York:Marcel Dekker, 1990;139-162.
8. Wakefield JC, Smith AFM, Racine-Poon A, Gelfand AE. Bayesian analysis of linear and non-linear population models using the Gibbs sampler. Appl Stat - J Royal Stat Soc Series C 43:201-221 (1994).
9. Wakefield JC. The Bayesian analysis of population pharmacokinetic models. J Am Stat Soc 91:62-75 (1995).
10. Bois FY, Gelman A, Jiang J, Maszle DR, Zeise L, Alexeef G. Population toxicokinetics of tetrachloroethylene. Arch Toxicol 70:347-355 (1996).
11. Woodruff TJ, Bois FY. Optimization issues in physiological toxicokinetic modeling - a case study with benzene. Toxicol Lett 69:181-196 (1993).
12. Pekari K, Vainiotalo S, Heikkilä P, Palotie A, Luotamo M, Riihimäki V. Biological monitoring of occupational exposure to low levels of benzene. Scand J Work Environ Health 18:317-322 (1992).
13. Gelman A, Bois F, Jiang J. Physiological pharmacokinetic analysis using population modeling ana informative prior distributions. J Am Stat Assoc (in press).
14. Thomas A, Spiegelhaiter DJ, Gilks WR. BUGS: a program to perform Bayesian inference using Gibbs sampling. In: Bayesian Statistics 4 (Bernardo JM, Berger JO, Dawid AP, Smith AFM, eds). Oxford:Oxford University Press, 1992;837-842.
15. Adolph EF. Quantitative relations in the physiological constitution of mammals. Science 109:579-585 (1949).
16. Davidson IWF, Parker JC, Beliles RP. Biological basis for extrapolation across mammalian species. Regul Toxicol Pharmacol 6:211-237 (1986).
17. Ings RM. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20:1201-1231 (1990).
18. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-1040 (1986).
19. ICRP. Report of the Task Group on Reference Man - A Report Prepared by a Task Group of Committee 2 of the International Commission on Radiological Protection. Oxford: Pergamon Press, 1975.
20. Williams LR, Leggett RW. Reference values for resting blood flow to organs of man. Clin Phys Physiol Meas 10:187-217 (1989).
21. Astrand I. Effect of physical exercise on uptake, distribution and elimination of vapors in man. In: Modeling of Inhalation Exposure to Vapors: Uptake, Distribution, and Elimination (Fiserova-Bergerova F, ed). Boca Raton, FL:CRC Press, 1983;107-130.
22. Medinsky MA, Sabourin PJ, Lucier G, Birnbaum LS, Henderson RF. A physiological model for simulation of benzene metabolism by rats and mice. Toxicol Appl Pharmacol 99:193-206 (1989).
23. Travis CC, Quillen JL, Arms A. Pharmacokinetics of benzene. Toxicol Appl Pharmacol 102:400-420 (1990).
24. Bois FY, Woodruff TJ, Spear RC. Comparison of three physiologically-based pharmacokinetic models of benzene disposition. Toxicol Appl Pharmacol 110:79-88 (1991).
25. Watanabe K, Bois F, Daisey J, Auslander D, Spear R. Benzene toxicokinetics in humans - bone marrow exposure to metabolites. Occup Environ Med 51:414-420 (1994).
26. Fiserova-Bergerova V. Gases and their solubility: a review of fundamentals. In: Modeling of Inhalation Exposure to Vapors: Uptake, Distribution, and Elimination (Fiserova-Bergerova F, ed). Boca Raton, FL:CRC Press, 1983;3-28.
27. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 2nd Ed. Philadelphia:Lea & Febiger, 1989.
28. Docter HJ, Zielhuis RL. Phenol excretion as a measure of benzene exposure. Ann Occup Hyg 10:317-326 (1967).
29. Gelfand AE, Smith AFM. Sampling-based approaches to calculating marginal densities. J Am Stat Assoc 85:398-409 (1990).
30. Gelman A. Iterative and non-iterative simulation algorithms. Comput Sci Stat 24:433-438 (1992).
31. Smith AFM. Bayesian computational methods. Phil Transac Royal Soc London, Series A 337:369-386 (1991).
32. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences (with discussion). Stat Sci 7:457-511 (1992).
33. 13C6]benzene. Cancer Res 54:4907-4914 (1994).
34. Smith MT. Mechanistic studies of benzene toxicity: implications for assessment. In: Biological Reactive Intermediates. 5: Basic Mechanistic Research in Toxicology and Human Risk Assessment (Snyder R, Sipes GI, Kalf GF, eds). New York:Plenum Press, 1996;259-266.
35. Hoener B-A. Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm Drug Dispos 15:295-304 (1994).
36. Seaton MJ, Schlosser PM, Bond JA, Medinsky MA. Benzene metabolism by human liver microsomes in relation to cytochrome P450 2E1 activity. Carcinogenesis 15:1799-1806 (1994).